Comparison of effects of different doses of spironolactone in treating heart failure of ischemic cardiomyopathy#br#
LU Zhike1, SUN Rong2*
2018, 38(9):
1002-1006.
doi:10.3969/j.issn.10073205.2018.09.003
Asbtract
(
823 )
PDF (386KB)
(
191
)
Related Articles |
Metrics
[Abstract]〓Objective〖HTSS〗〓To observe the effects of different doses of spironolactone on cardiac structure and function in patients with heart failure of ischemic cardiomyopathy.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 120 patients with ischemic heart disease and heart failure were selected as study subjects. According to the random number table method, they were divided into control group, lowdose spironolactone group, middledose spironolactone group, and largedose spironolactone group, with 30 cases in each group. The control group given conventional treatment, lowdose spironolactone group plus 10 mg spironolactone, mediumdose spironolactone group with 20 mg spironolactone, highdose spironolactone group plus 40 mg spironolactone. The left ventricular ejection fraction(LVEF), left ventricular endsystolic diamete(LVESD), left ventricular enddiastolic diameter(LVEDD), nocardial function classificationin New York Heart Association(NYHA), Nterminal proBtype natriuretic peptide(NTproBNP), cardiac troponin T(cTnT), high sensitivity Creactive protein(hsCRP), tumor necrosis factorα(TNFα), procollagen type Ⅲ nitrogen terminal peptide(PⅢNP), 6 min walking distance and clinical efficacy were compared among different groups.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The clinical efficacy of the middledose spironolactone group was better than that of the control group, and the total treatment efficiency was higher than that of the control group(P<005).After treatment, the levels of NTproBNP, cTnT, hsCRP, TNFα, and PⅢNP in the 4 groups were lower than before treatment.The levels of NTproBNP, hsCRP, TNFα, and PⅢNP in lowdose spironolactone group, middledose spironolactone group, and largedose spironolactone group were lower than those in the control group. The level of cTnT in the middledose spironolactone group was lower than that in the control group. The levels of NTproBNP, hsCRP, TNFα, and PⅢNP in the middledose spironolactone group were lower than those in the lowdose spironolactone group and the highdose spironolactone group(P<005).The LVEF value and 6 min walking distance of the 4 groups were greater than before treatment. The LVESD value, LVEDD value and NYHA functional class were less than before treatment. The LVEF value and 6 min walking distance of smalldose spironolactone group, middledose spironolactone group, and largedose spironolactone group were greater than those of the control group. NYHA cardiac function was less than the control group. The LVEDD value of the middledose spironolactone group was lower than that of the control group, and the NYHA heart function of the middledose spironolactone group. The grading was smaller than that of the smalldose spironolactone group and the largedose spironolactone group, and 6 min walking distance was greater than that of the smalldose spironolactone group and the highdose spironolactone group(P<005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Compared with the 10 mg and 40 mg dose groups, the 20 mg dose of spironolactone can effectively control the ventricular remodeling in patients with ischemic cardiomyopathy heart failure, which will benefit the improvement of cardiac function and is worthy of clinical application.